Melancholic depression is a severe subtype of major depressive disorder characterized by a complete loss of pleasure, lack of mood reactivity, and distinct physical symptoms. Finding effective treatment is essential, as this form of depression significantly impacts daily functioning and quality of life. Depression (also called major depressive disorder or clinical depression) can cause severe symptoms that affect how you feel, think, and handle daily activities. Classic melancholic depression features include insomnia, weight loss, and psychomotor changes.
The good news is that effective treatments are available. We're working to improve existing treatments like medications, talk therapy (including telehealth and online options), and brain stimulation therapy. Treatments include psychotherapy or talk therapy, medication, and sometimes brain stimulation therapy. These treatments may also be used in combination with one another. With proper care, most people with melancholic depression can achieve significant improvement in their symptoms and return to meaningful daily activities.
Table of Contents
- Understanding Melancholic Depression
- Therapy for Melancholic Depression
- Medication for Melancholia
- Brain Stimulation Therapies
- Complementary and Alternative Treatments
- Helping a Loved One with Melancholia
- Finding the Right Treatment Approach
- Frequently Asked Questions
- How Therapy Can Help
Understanding Melancholic Depression
Melancholic depression is recognized in the DSM-5-TR as a specifier for major depressive disorder, indicating specific features that distinguish it from other forms of depression. The DSM-5 specifier "with melancholic features" is also used as a diagnosis specifier in bipolar disorder. In depression with melancholic features, either a loss of pleasure in almost all activities or a lack of reactivity to usually pleasurable stimuli is present. According to DSM-5-TR, this subtype is applied only when there is a near-complete absence of the capacity for pleasure, not merely a diminution.
To receive this diagnosis, individuals must experience either complete anhedonia (inability to feel pleasure) or lack of mood reactivity to positive events, plus at least three of the following symptoms:
- Distinct quality of depressed mood (different from grief or sadness)
- Depression regularly worse in the morning
- Early morning awakening (at least 2 hours before usual time)
- Significant psychomotor agitation or retardation
- Significant weight loss or anorexia
- Excessive or inappropriate guilt
Therapy for Melancholic Depression
While melancholic depression can be more resistant to psychotherapy alone compared to other depression types, therapy remains an important component of comprehensive treatment. In comparison to those with nonmelancholic mood disorders, melancholic patients rarely respond to placebos, psychotherapies, or social interventions. However, when combined with medication, therapy can be highly beneficial.
Cognitive Behavioral Therapy (CBT)
CBT helps individuals identify and change negative thought patterns and behaviors. For melancholic depression, therapists may focus on:
- Cognitive restructuring to address excessive guilt and self-criticism
- Behavioral activation to combat psychomotor retardation
- Problem-solving strategies for managing daily challenges
- Relapse prevention techniques
We analyzed interventions by class and individually. The primary efficacy outcome was depressive symptom change (expressed as standardised mean difference [SMD]). For less severe depression, group cognitive/cognitive behavioural therapy (CT/CBT) class was efficacious versus treatment as usual [TAU], the reference treatment for this population [SMD -1.01 (95% Credible Interval [CrI] -1.76; -0.06)].
Interpersonal Therapy (IPT)
IPT addresses interpersonal issues that may contribute to or result from depression, focusing on:
- Role transitions and life changes
- Interpersonal disputes and conflicts
- Grief and loss
- Social isolation and skill deficits
Group Therapy
Group therapy can provide valuable social support and reduce isolation. In more severe depression, combined group exercise with antidepressants emerged as efficacious versus pill placebo (albeit based on a more limited evidence base than other efficacious classes in this population). Additional treatments showed evidence of efficacy at the intervention level. Benefits include:
- Shared experiences with others facing similar challenges
- Learning coping strategies from peers
- Developing social connections
- Reducing stigma and shame
Medication for Melancholia
Antidepressant medications are typically the first-line treatment for melancholic depression. Research suggests certain medications may be particularly effective for this subtype.
Types of Antidepressants
Tricyclic Antidepressants (TCAs)
Melancholic patients respond better to broad-action tricyclic antidepressants than to narrow-action antidepressants (e.g., serotonin uptake inhibitors). Melancholic symptom features are predictive of a positive response to ECT and to tricyclic antidepressants in the severely ill. While older, TCAs like amitriptyline and nortriptyline may be particularly effective for melancholic features.
Selective Serotonin Reuptake Inhibitors (SSRIs)
Selective serotonin reuptake inhibitors [-0.24 (-0.32; -0.16)] SSRIs remain a common choice due to their favorable side effect profile, though they may be somewhat less effective than TCAs for melancholic features.
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Serotonin and norepinephrine reuptake inhibitors [-0.32 (-0.43; -0.22)] Medications like venlafaxine and duloxetine target multiple neurotransmitter systems.
Other Options
Mirtazapine [-0.35 (-0.48; -0.22)] Mirtazapine and other atypical antidepressants may also be effective.
Important Considerations
Overall, almost 70% of patients with depression in the study were helped by one or more drugs. Approximately 40% achieved remission of symptoms on their first drug and 30% in the second. On the third and fourth tries, 14% and 13% respectively achieved remission.
Treatment often requires patience and persistence. Many individuals need to try multiple medications before finding the most effective option with tolerable side effects.
Brain Stimulation Therapies
Electroconvulsive Therapy (ECT)
ECT remains one of the most effective treatments for severe melancholic depression, particularly when other treatments have failed. A study by the Consortium for Research on Electroconvulsive Therapy (CORE), which involved 311 patients with depression, showed that the remission rate for patients with melancholy depression was 62.1%. They respond well to ECT. Melancholic symptom features are predictive of a positive response to ECT and to tricyclic antidepressants in the severely ill.
Modern ECT is:
- Performed under general anesthesia
- Much safer than historical versions
- Associated with response rates of 70-80% in treatment-resistant depression
- Particularly effective for melancholic features
Although ECT can be considered a first-line and relatively rapid treatment for psychotic depression, the utility of other clinical features in predicting outcomes with ECT is less clear. The most recent systematic review and meta-analysis of predictive clinical factors found that the presence of psychosis (odds ratio 1.47, 95% CI 1.16–1.85) and, to a much lesser extent, older age (standard mean difference 0.26, 95% CI 0.13–0.38), predicted remission with ECT. Of note, the presence of melancholia did not significantly predict remission or response following ECT; however, greater overall depression severity modestly predicted response (standard mean difference 0.19, 95% CI 0.07–0.31), but not remission. Psychomotor disturbances that are core features of both melancholia and catatonia, such as agitation and retardation, may mediate the predictive value of illness severity.
Newer Brain Stimulation Approaches
Repetitive Transcranial Magnetic Stimulation (rTMS)
Comparing the effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in the treatment of depression: A systematic review and meta-analysis. Non-invasive treatment using magnetic fields to stimulate specific brain regions.
Ketamine and Esketamine
Depression symptoms can be hard to manage, especially for people with treatment-resistant depression, a persistent and severe form of the disorder. Fortunately, new therapies are emerging for such hard-to-treat conditions. One of these is the medication ketamine, which numerous NIMH-funded studies have shown has fast-acting and lasting effects in people with mood disorders like depression. The discovery of ketamine has been a game changer for people with severe depression, who often need rapid relief from life-threatening symptoms. Rapid-acting treatments showing promise for severe depression.
Cranial Electrotherapy Stimulation (CES)
An emerging, FDA-cleared treatment for depression, anxiety, and insomnia. To the best of our knowledge, our meta-analysis presents the most comprehensive evidence to date on the efficacy, safety, and acceptability of CES for alleviating depressive symptoms and improving quality of life in adults with primary and secondary depression. The results revealed a small significant effect in reducing depressive symptoms in adults, highlighting its potential as a therapy for depression management. CES was demonstrated to be both safe and well tolerated.
Recent research (2023-2025) shows CES may offer:
- Reduced depressive symptoms
- Improved sleep quality
- Minimal side effects
- Convenient home-based treatment option
Complementary and Alternative Treatments
Acupuncture
Recent systematic reviews and meta-analyses (2023-2024) demonstrate that acupuncture can be beneficial for depression. A pooled meta-analysis of 11 studies using HAMD scores as a measure confirmed the significant efficacy of acupuncture for depression (RR: −1.63; 95% CI: −2.49 to −0.76; P = 0.0002; I2 = 86%; n = 1,668). Nine meta-analyses using HAMD-derived efficacy rates as an instrument showed that acupuncture exhibited significant efficacy in depression (RR: 2.6; 95%; CI: 1.6 to 4.23; P = 0.0001; I2 = 0; n = 614). Three studies showed that acupuncture reduced susceptibility to antidepressant-related side effects.
Key findings include:
- Significant reduction in depression severity
- Fewer side effects compared to medication alone
- Effective as adjunct to standard treatment
- Potential for use when medications are contraindicated
Acupuncture showed clinically significant reductions in the severity of depression compared to usual care (Hedges (g) = 0.41, 95% confidence interval (CI) 0.18 to 0.63), sham acupuncture (g = 0.55, 95% CI 0.31 to 0.79), and as an adjunct to anti-depressant medication (g = 0.84, 95% CI 0.61 to 1.07). A significant correlation between an increase in the number of acupuncture treatments delivered and reduction in the severity of depression (p = 0.015) was found.
Exercise and Physical Activity
In more severe depression, combined group exercise with antidepressants emerged as efficacious versus pill placebo. Regular physical activity can:
- Improve mood and energy levels
- Combat psychomotor retardation
- Enhance sleep quality
- Provide social interaction opportunities
Mindfulness and Meditation
While less studied specifically for melancholic depression, mindfulness-based interventions may help with:
- Managing negative thought patterns
- Reducing stress and anxiety
- Improving emotional regulation
- Enhancing overall well-being
Helping a Loved One with Melancholia
Supporting someone with melancholic depression requires understanding and patience. Here are evidence-based strategies:
Morning Support
A depressed mood that is distinctly different from the kind that is felt when a loved one is deceased. Since symptoms are often worst in the morning:
- Help establish a gentle morning routine
- Provide encouragement without pressure
- Assist with basic tasks if needed
- Be present without overwhelming
Practical Assistance
- Meal preparation: Depression often affects appetite and energy
- Transportation: Offer rides to appointments
- Medication reminders: Help maintain treatment consistency
- Activity planning: Suggest low-key, manageable activities
Communication Tips
- Use non-judgmental language
- Avoid phrases like "snap out of it" or "just think positive"
- Validate their experience
- Express consistent support and care
Crisis Management
If you or someone you know is struggling or having thoughts of suicide, call or text the 988 Suicide & Crisis Lifeline at 988 or chat at 988lifeline.org. In life-threatening situations, call 911.
Finding the Right Treatment Approach
Comprehensive Assessment
A thorough evaluation by a mental health professional should include:
- Detailed symptom history
- Assessment of melancholic features
- Medical history and physical examination
- Consideration of co-occurring conditions
- Previous treatment responses
Treatment Planning
Effective treatment for melancholic depression often involves:
1. Initial stabilization with medication and/or ECT
2. Combination therapy incorporating psychotherapy
3. Lifestyle modifications including exercise and sleep hygiene
4. Regular monitoring and adjustment of treatment
5. Relapse prevention strategies
Current Depression Statistics
Most recent 2024 data show 5% or 1 in 20 U.S. adults regularly reported feelings of depression. Most recent 2024 data show 19% or 1 in 5 U.S. adults were ever told by a doctor or other healthcare professional that they had any type of depression disorder. During August 2021–August 2023, 13.1% of U.S. adolescents and adults age 12 and older had depression in a given 2-week period.
New data from CDC's National Center for Health Statistics indicate that the prevalence of depression in U.S. adolescents and adults increased 60% in the past decade, according to data from the National Health and Nutrition Examination Survey (NHANES). Depression prevalence has nearly doubled, from 7.3% in 2015-16 to more than 13% in 2021-23.
Case Examples of Melancholia Treatment
Case 1: Comprehensive Treatment Approach Maria, 58, presented with severe melancholic depression characterized by complete anhedonia, early morning awakening, and significant psychomotor retardation. After two failed medication trials, her treatment team recommended:
- ECT (12 sessions over 6 weeks)
- Transition to nortriptyline maintenance
- Weekly CBT focusing on behavioral activation
- Gradual return to morning yoga practice
Result: 75% improvement in symptoms within 8 weeks, sustained remission at 6 months with continued medication and monthly therapy.
Case 2: Integrative Treatment Success David, 42, experienced melancholic depression with prominent guilt and weight loss. His treatment included:
- SNRI medication (duloxetine)
- Adjunctive acupuncture for residual symptoms
- Group therapy for social re-engagement
- Structured exercise program
Result: Achieved remission within 12 weeks, maintained with continued medication and lifestyle interventions.
Frequently Asked Questions
How is melancholic depression different from regular depression?
Melancholic depression is characterized by a complete loss of pleasure (not just reduced enjoyment), lack of mood reactivity even to positive events, and distinct physical symptoms like early morning awakening and psychomotor changes. Melancholy means there is a near-complete absence of the capacity for pleasure, not just diminished pleasure. The "distinct quality" of mood that is characteristic of the "with melancholic features" specifier is experienced as qualitatively different from that during a non-melancholic depressive episode. A depressed mood that is described as merely more severe, longer lasting, or present without a reason is not considered distinct in quality, and does not meet the criteria for melancholic features.
What treatments work best for melancholic depression?
Research indicates that melancholic depression often responds best to:
- Tricyclic antidepressants (especially in severe cases)
- Electroconvulsive therapy (ECT)
- Combination of medication and structured psychotherapy
Melancholic patients respond better to broad-action tricyclic antidepressants than to narrow-action antidepressants (e.g., serotonin uptake inhibitors). They respond well to ECT. In comparison to those with nonmelancholic mood disorders, melancholic patients rarely respond to placebos, psychotherapies, or social interventions.
Can melancholic depression be treated without medication?
While melancholic depression typically requires medication or brain stimulation therapies for optimal outcomes, complementary approaches can enhance recovery:
- Acupuncture has shown significant benefits in recent studies
- Exercise combined with standard treatment improves outcomes
- Psychotherapy is valuable when combined with medical treatment
How long does treatment typically take?
Treatment duration varies, but many people experience:
- Initial improvement within 4-6 weeks of starting medication
- More rapid response (1-2 weeks) with ECT or ketamine treatments
- Full remission may take 3-6 months
- Maintenance treatment often continues for 6-12 months after remission
What about treatment for postpartum depression with melancholic features?
Recent advances include FDA-approved treatments specifically for postpartum depression:
Women with severe PPD who received zuranolone showed statistically significant and clinically meaningful improvements in depression symptoms compared to women who received a placebo. These effects were rapid, sustained through 45 days, and seen across a range of clinical measures. The benefits were mirrored in patients' self-assessment of their depression symptoms.
- Zuranolone: Oral medication taken for 14 days
- Brexanolone: IV infusion with rapid effects
How Therapy Can Help
If you're experiencing melancholic depression, professional help can make a significant difference. A qualified therapist can:
- Provide accurate diagnosis and assessment
- Develop a personalized treatment plan
- Coordinate care with psychiatrists or other providers
- Offer evidence-based psychotherapy
- Monitor progress and adjust treatment as needed
- Support long-term recovery and relapse prevention
Learn how to find help for yourself or someone else. You can also find support and locate mental health services in your area on the Substance Abuse and Mental Health Services Administration website.
Remember, melancholic depression is a treatable condition. With proper care combining medication, therapy, and supportive interventions, recovery is not only possible but probable. Don't hesitate to reach out for help – effective treatments are available, and you deserve to feel better.
[Find a therapist who specializes in depression treatment →](/find-a-therapist)
References:
- American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing.
- Anand, A., Mathew, S. J., Sanacora, G., et al. (2023). Ketamine versus ECT for nonpsychotic treatment-resistant major depression. New England Journal of Medicine, 388, 2315-2325. https://doi.org/10.1056/NEJMoa2302399
- Belge, J. B., van Eijndhoven, P., & Mulders, P. C. R. (2024). Mechanism of action of ECT in depression. Current Topics in Behavioral Neurosciences, 66, 279-295. https://doi.org/10.1007/7854_2023_450
- Centers for Disease Control and Prevention. (2025). Depression prevalence in adolescents and adults: United States, August 2021–August 2023. NCHS Data Brief, No. 527. Retrieved from https://www.cdc.gov/nchs/data/databriefs/db527.pdf
- Centers for Disease Control and Prevention. (2026). Mental Health Conditions & Care. Retrieved from https://www.cdc.gov/mental-health/about-data/conditions-care.html
- Chen, X., Wu, L., Zhang, Y., et al. (2023). Efficacy and safety of acupuncture for depression: A systematic review and meta-analysis of randomized control trials. Research in Nursing & Health, 46(3), 287-301. https://doi.org/10.1002/nur.22284
- Chu, C. S., Chang, C. H., Pan, C. C., et al. (2024). Effect of cranial electrotherapy stimulation as an add-on therapy on late-life generalized anxiety disorder: An open-label study. Journal of the Formosan Medical Association, 123(7), 781-787. https://doi.org/10.1016/j.jfma.2023.12.002
- Deligiannidis, K. M., Meltzer-Brody, S., et al. (2023). Effect of zuranolone vs placebo in postpartum depression: A randomized clinical trial. JAMA Psychiatry, 80(8), 824-833. https://doi.org/10.1001/jamapsychiatry.2023.1559
- Dold, M., Bartova, L., Souery, D., et al. (2021). Melancholic features in major depression – a European multicenter study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 110, 110330. https://doi.org/10.1016/j.pnpbp.2021.110330
- Furukawa, T. A., Shinohara, K., Sahker, E., et al. (2020). Melancholic features (DSM-IV) predict but do not moderate response to antidepressants in major depression: An individual participant data meta-analysis of 1219 patients. European Archives of Psychiatry and Clinical Neuroscience, 270(4), 521-532. https://doi.org/10.1007/s00406-019-01035-8
- Lam, R. W., Kennedy, S. H., Adams, C., et al. (2024). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. Canadian Journal of Psychiatry, 69(9), 641-687. https://doi.org/10.1177/07067437241245384
- Mavranezouli, I., Megnin-Viggars, O., Pedder, H., et al. (2024). A systematic review and network meta-analysis of psychological, psychosocial, pharmacological, physical and combined treatments for adults with a new episode of depression. eClinicalMedicine, 75, 102780. https://doi.org/10.1016/j.eclinm.2024.102780
- National Alliance on Mental Illness (NAMI). (2024). Latest NIMH study results—Treatment of depression. Retrieved from https://www.nami.org/press-releases/latest-nimh-study-results-treatment-of-depression/
- National Institute of Mental Health. (2024). Basic research powers the first medication for postpartum depression. Retrieved from https://www.nimh.nih.gov/news/science-updates/2024/basic-research-powers-the-first-medication-for-postpartum-depression
- National Institute of Mental Health. (2024). Depression - National Institute of Mental Health (NIMH). Retrieved from https://www.nimh.nih.gov/health/topics/depression
- Parikh, S. V., Quilty, L. C., Ravitz, P., et al. (2024). Zuranolone combined with standard-of-care antidepressants in major depressive disorder: Results from the CORAL study. Journal of Clinical Psychiatry, 85(3), 23m15134. https://doi.org/10.4088/JCP.23m15134
- Parker, G., Fink, M., Shorter, E., et al. (2010). Issues for DSM-5: Whither melancholia? The case for its classification as a distinct mood disorder. American Journal of Psychiatry, 167(7), 745-747. https://doi.org/10.1176/appi.ajp.2010.09101525
- Perry, P. J. (1996). Pharmacotherapy for major depression with melancholic features: Relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. Journal of Affective Disorders, 39(1), 1-6. https://doi.org/10.1016/0165-0327(96)00014-6
- Raja, S. M., Guptill, J. T., Mack, M., et al. (2024). A phase 1 assessment of the safety, tolerability, pharmacokinetics and pharmacodynamics of (2R,6R)-hydroxynorketamine in healthy volunteers. Clinical Pharmacology & Therapeutics, 116(5), 1314-1324. https://doi.org/10.1002/cpt.3391
- Ren, C., Li, S., Wang, Y., et al. (2025). Transcranial electrical stimulation in treatment of depression: A systematic review and meta-analysis. JAMA Network Open, 8(6), e2517864. https://doi.org/10.1001/jamanetworkopen.2025.17864
- Richardson, E., Patterson, R., Meltzer-Brody, S., et al. (2025). Transformative therapies for depression: Postpartum depression, major depressive disorder, and treatment-resistant depression. Annual Review of Medicine, 76, 81-93. https://doi.org/10.1146/annurev-med-050423-095712
- Rush, A. J., Weissenburger, J. E. (1994). Melancholic symptom features and DSM-IV. American Journal of Psychiatry, 151(4), 489-498. https://doi.org/10.1176/ajp.151.4.489
- Semkovska, M., & McLoughlin, D. M. (2023). Subjective cognitive complaints and subjective cognition following electroconvulsive therapy for depression: A systematic review and meta-analysis. Australian & New Zealand Journal of Psychiatry, 57(1), 21-33. https://doi.org/10.1177/00048674221089231
- Smith, C. A., Armour, M., Lee, M. S., Wang, L. Q., & Hay, P. J. (2018). Acupuncture for depression. Cochrane Database of Systematic Reviews, 3(3), CD004046. https://doi.org/10.1002/14651858.CD004046.pub4
- Tan, R., Duan, Y., & Wen, Y. (2024). Efficacy of acupuncture for depression: A systematic review and meta-analysis. Frontiers in Neuroscience, 18, 1347651. https://doi.org/10.3389/fnins.2024.1347651
- Terlizzi, E. P., & Zablotsky, B. (2024). Symptoms of anxiety and depression among adults: United States, 2019 and 2022. National Health Statistics Reports, No 213. Retrieved from https://www.cdc.gov/nchs/data/nhsr/nhsr213.pdf
- Valerio, M. P., Lomastro, J., Martino, D. J. (2023). Melancholic features and treatment outcome to selective serotonin reuptake inhibitors in major depressive disorder: A re-analysis of the STARD trial. Journal of Affective Disorders*, 340, 320-327. https://doi.org/10.1016/j.jad.2023.08.057
- van Diermen, L., van den Ameele, S., Kamperman, A. M., et al. (2018). Prediction of electroconvulsive therapy response and remission in major depression: Meta-analysis. British Journal of Psychiatry, 212(2), 71-80. https://doi.org/10.1192/bjp.2017.28
- Xu, G., Xiao, Q., Huang, B., et al. (2023). Clinical evidence for association of acupuncture with improved major depressive disorder: A systematic review and meta-analysis. Neuropsychobiology, 82(1), 1-13. https://doi.org/10.1159/000527903
